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APOBEC3G is a DNA cytidine deaminase that has
antiviral activity against HIV-1 and other pathogenic
viruses. In this study the crystal structure of the
catalytically active C-terminal domain was deter-
mined to 2.25 A˚. This structure corroborates features
previously observed in nuclear magnetic resonance
(NMR) studies, a bulge in the second b strand and
a lengthening of the second a helix. Oligomerization
is postulated to be critical for the function of
APOBEC3G. In this structure, four extensive intermo-
lecular interfaces are observed, suggesting potential
models for APOBEC3G oligomerization. The struc-
tural and functional significance of these interfaces
was probed by solution NMR and disruptive variants
were designed and tested for DNA deaminase and
anti-HIV activities. The variant designed to disrupt
the most extensive interface lost both activities.
NMR solution data provides evidence that another
interface, which coordinates a novel zinc site, also
exists. Thus, the observed crystallographic inter-
faces of APOBEC3G may be important for both olig-
omerization and function.
INTRODUCTION
APOBEC3G (A3G), a DNA cytidine deaminase, belongs to the
larger APOBEC family of proteins. Members include activation-
induced deaminase, APOBEC1, APOBEC2, APOBEC4, and, in
addition to A3G, six APOBEC3s (A3s) (Jarmuz et al., 2002;
Sawyer et al., 2004; Zhang and Webb, 2004; Conticello et al.,
2005; reviewed in Goila-Gaur and Strebel, 2008; Chiu and
Greene, 2008, 2009; Malim, 2009). These proteins have diverse
biological functions that include editing mRNA (APOBEC1),
diversifying antibody gene DNA (activation-induced deaminase),
and restricting the mobilization of retroviruses and retrotranspo-
sons (A3s).28 Structure 18, 28–38, January 13, 2010 ª2010 Elsevier Ltd All rightAll the A3s (A, B, C, DE, F, G, and H) are single-strand DNA
cytidine deaminases known to inhibit multiple retroelement
substrates. The deaminases possess either one or two con-
served zinc-coordinating (Z) motifs, with the consensus amino
acid signature Hx1Ex24-28PCx2-4C (Conticello, 2008; Jarmuz
et al., 2002; LaRue et al., 2008, 2009). Zinc coordination is medi-
ated by a histidine and two cysteines. The hydroxide that subse-
quently converts cytidine to uridine (C-to-U deamination) is
generated when the active site glutamate removes hydrogen
from water.
HIV-1, the retrovirus that causes AIDS, is the most prominent
pathogen restricted by A3G (Harris et al., 2003; Zhang et al.,
2003; Lecossier et al., 2003; Mangeat et al., 2003; Sheehy
et al., 2002). A3G suppresses HIV-1 infectivity by entering viral
particles and deaminating the viral cDNA cytidines to uridines
during reverse transcription. The uridines introduce adenosines
in the complementary genomic strand, which are often detected
as the hallmark G-to-A hypermutations. These mutations pro-
duce stop codons and amino acid changes that can ultimately
inactivate the virus. However, HIV-1 efficiently counteracts
restriction by A3G, with the viral Vif protein binding and targeting
the cytidine deaminase for proteasomal degradation (reviewed
in Goila-Gaur and Strebel, 2008; Chiu and Greene, 2008, 2009;
Malim, 2009).
The life-or-death interaction between human A3G and HIV-1
Vif has made A3G the prototype member of the APOBEC family
for biochemical and structural investigations. A3G has two
consecutive Z motifs giving the sequence of the enzyme an
internal pseudo-symmetry. In the past two years, significant
advances have been made in elucidating the structure of the
C-terminal catalytic domain of A3G (A3G-CTD) but the confor-
mations of several important functional regions differ between
three NMR structures and a single X-ray crystal structure
(Chen et al., 2008; Furukawa et al., 2009; Harjes et al., 2009;
Holden et al., 2008). The present study aims to resolve some
of the controversy by determining a new, higher-resolution
crystal structure of A3G-CTD. This new structure differs from
the recently reported crystal structure (PDB ID: 3E1U) (Holden
et al., 2008) and strongly supports the structural integrity of the
NMR structures (PDB 2JYW, 2KBO, and 2KEM) (Chen et al.,s reserved























R factor (%) 16.57
R free (%) 20.82
Water molecules per AU 379
Zinc atoms per AU 4
Ramachandran statistics (such residues per molecule)
‘‘additionally allowed’’ regions 12
‘‘generously allowed’’ regions 0
‘‘disallowed’’ regions 1
Figure 1. Crystal Structure of A3G191-384-2K3A
Crystal Structure of A3G191-384-2K3A with the a helices highlighted in red
and b sheets highlighted in yellow, labeled as in Harjes et al. (2009). The cata-
lytic zinc ion is shown in cyan and the intermolecular zinc ion is shown in
magenta in this and subsequent figures.
Structure
Correct APOBEC3G Catalytic Domain Crystal Structure2008; Furukawa et al., 2009; Harjes et al., 2009). Most impor-
tantly, this newcrystal structure reveals four extensive interfaces,
of which one or more may be important for A3G oligomerization
and biological activity.
RESULTS
The crystal structure of the human APOBEC3G catalytic domain
A3G191-384-2K3A, where 2K3A is L234K, C243A, F310K,
C321A, and C356A (Harjes et al., 2009), was determined at
2.25 A˚ resolution. The A3G191-384-2K3A crystal structure was
solved by molecular replacement, using a highly truncated
model based on PDB 3E1U (Holden et al., 2008). The crystal
structure contains two molecules of A3G191-384-2K3A in the
asymmetric unit. The final refinement statistics are: R factor (R
free) 16.57% (20.82%) (Table 1).
The crystal structure of A3G191-384-2K3A has a core a-b-a
fold consistent with other cytidine deaminases (Chen et al.,
2008; Holden et al., 2008; Prochnow et al., 2007). As seen with
the other A3G-CTD structures (Harjes et al., 2009; Holden et al.,
2008), this structure has a five stranded b sheet surrounded on
both sides by six a helices (Figure 1). Secondary structural
elements are numbered after the A3G191-384-2K3A NMR struc-Structure 18,ture (PDB 2KEM) (Harjes et al., 2009) so that consistent compar-
isonscanbemadebetween thestructures. Thesecondb strand is
discontinuous, as also observed in thewild-type A3G-CTD (Furu-
kawa et al., 2009) and A3G-CTD-2K3A (Chen et al., 2008; Harjes
et al., 2009)NMRstructures. Aspreviously observed, thecatalytic
zinc is coordinated directly by H257, C288, and C291 and indi-
rectly by the catalytic residue E259 via a water molecule. Thus,
in termsof the overall fold, this structure is similar to thepreviously
published structures but many key specific differences exist.Crystal Structure Comparison
Comparison of A3G191-384-2K3A with the 3E1U crystal struc-
ture reveals numerous differences (highlighted in green and
blue in Figure 2A). Some of these differences are in loop regions
but other variations include large regions of secondary structure,
notably the b1-b2 region (M227-Q237), the b20-a2 region (H248-
G255), and the a2-b3 region (P267-D274). In the A3G191-384-
2K3A crystal structure, the second b strand is discontinuous,
with residues L235-R239 forming a prominent ‘‘bulge.’’ This
has been observed in both mutant and wild-type A3G-CTD
NMR structures (Furukawa et al., 2009; Harjes et al., 2009;
Chen et al., 2008).
Crystallography and NMR spectroscopy are complementary
techniques with well-established methods for verifying the struc-
tural integrityof protein structures.PDB_REDOrecently organized
some of the verification of crystal structures in the Protein Data
Bank (Joosten et al., 2009b, 2009a; Sanderson, 2009). Unfortu-
nately, the only other A3G-CTD crystal structure in the database
was flagged as having discrepancies in the PDB_REDOdatabase
(PDB 3E1U with R factor 25.2%, R free 26.7%, and resolution
2.3 A˚). Many of the regions in the 3E1U structure (Holden et al.,28–38, January 13, 2010 ª2010 Elsevier Ltd All rights reserved 29
Figure 2. A Comparison of the A3G191-384-
2K3A and 3E1U Structures
(A) Major regions of structural differences between
A3G191-384-2K3A and 3E1U highlighted in blue
and green. Residues F268-D272, which were mis-
traced in the 3E1U structure, are highlighted in red.
(B) NOE violations of more than 6 A˚ (red lines con-
necting a-carbon atoms) calculated based on the
A3G191-384-2K3A structure’s NMR data (PDB
2KEM) (Harjes et al., 2009).
(C) Differences in a carbon B factors. Color spec-
trum blue to red depicts lowest to highest values.
The overall a carbon B factor range for the
A3G191-384-2K3A crystal structure is 13.0–
52.18 A˚2, compared to 15.34–62.17 A˚2 for the
3E1U crystal structure.
(D) 2Fo-Fc electron density maps, contoured at
sigma level 1.0, show the placement of residues
F268-D272 in three different structures: (1) the
original and incorrect 3E1U, (2) the rebuilt and cor-
rected 3E1U, and (3) the correct A3G191-384-
2K3A crystal structure.
*While this paper was in press the Protein Data Bank lists a new entry, 3IQS as
the updated version of 3E1U. This new entry has the same primary citation as
3E1U, but has corrected the mis-traced residues (Figure 2D) R-factor 25.1,
Rfree 26.3.
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3E1U structure’s experimental data are the weakest (a carbon B
factors shown in Figure 2C). The regions differing between these
structures include b1-b2, b20-a2, and a2-b3.
Evidence for ambiguity in the 3E1U structure is apparent in four
ways: (1) 36 NOE restraints are violated in the 3E1U structure by
more than 6 A˚, with respect to NMR structural data, including in
the very well-ordered a-helical and b sheet regions that are well
established by NMR (Figure 2B and Experimental Procedures).
(2) In addition to being flagged in PDB-REDO, analyses of the30 Structure 18, 28–38, January 13, 2010 ª2010 Elsevier Ltd All rights reservedstructure and experimental structure
factors of the 3E1U structure, down-
loaded from the Protein Data Bank
(http://www.rcsb.org), revealed seven
residues that were in unfavorable Rama-
chandran space (three in disallowed and
four in generously allowed regions).
Most significantly, residues F268-D272
are completely mistraced in the electron
density, burying K270 away from the
surface (Figure 2D).* These residues,
located near the end of a2 helix, may be
essential for the stability of the A3G-CTD
active site because mutating W269 or
L271 abrogates deaminase activity
(Chen et al., 2008). When we refit this
region in the 3E1U data, the final turn of
a2 helix fit better within the electron
density (Figure 2D). Thus, the structure
in this region converged toward the
conformation observed in the NMR struc-
tures not the one originally modeled in the
3E1U structure. The electron density in
two other regions, b1-b2 and b20-a2, re-
mained ambiguous,making refitting unat-
tainable. (3) In contrast to these regions in
the 3E1U structure, our crystal structureof A3G-191-384-2K3A (R factor 16.57%, R free 20.82%, and
resolution 2.25 A˚) is well ordered. Our structure of A3G191-
384-2K3Ahas only nineNOE restraint violations to theNMRdata;
the a2 helix is well ordered; and the structure has lower a carbon
B factors (Table 1 and Figure 2). (4) Mass spectrometry analysis
Figure 3. Interface 1 between Two A3G-CTDMolecules in the Asym-
metric Unit
Surface representation (A) and details (B) of the largest interaction interface.
Molecule A is shown in dark green and molecule B is shown in light green.
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In contrast to the 3E1U structure, all NMR structures and the
A3G191-384-2K3A crystal structure show that residues M227
and W232 are adjacent to each other in the two neighboring
b strands (b1-b2). This was verified by introducing two cysteine
mutations, M227C in b1 and W232C in b2, into both full-length
A3G-2K3A (see Figure S1 available online) and A3G (data not
shown). Mass spectrometry determined that these two residues
form a disulfide bond and no peptides containing free M227C or
W232C are detected in either construct. In the 3E1U structure,
M227 and W232 are not adjacent, rather R226 and L235 (part
of the putative ‘‘continuous b2’’ strand) face each other. Applying
similarmass spectrometry analysis to full-length A3G,withmuta-
tions R226C and L235C, did not result in a detectable peptide
containing a disulfide bond (data not shown).
The authors of the 3E1U structure write, ‘‘Therefore, an intact
full-length b2 strand and the five-stranded b-sheet core is
probably the feature of wild-type APOBEC3G-CD2 and all other
APOBEC proteins’’ (Holden et al., 2008). However, the A3G-191-
384-2K3A crystal structure and the additional experimental data
described above do not support this statement. These data
suggest that the bulge observed between the b2-b20 strands in
NMR experiments and the A3G-191-384-2K3A crystal structure
is not merely an experimental artifact but an intrinsic feature of
A3G-CTD structure.
Analysis of A3G191-384-2K3A Crystal Packing
Interfaces
The two molecules in the asymmetric unit in the crystal structure
of A3G191-384-2K3A pack in such a way as to produce four
major interfaces, all of which are the result of non-crystallo-
graphic symmetry, with surface areas of 901 A˚2, 604 A˚2,
427 A˚2, and 246 A˚2, respectively (Figures 3–6). Multiple sequence
alignment of the A3G-CTD to the ten other human A3 zinc-
coordinating domains (A3G-NTD, A3A, A3B-CTD/NTD, A3C,
A3DE-NTD/CTD, A3F-NTD/CTD, and A3H) reveals that many
of the residues contributing more than 30 A˚2 to these interfaces
are unique to A3G-CTD (Figure 7).
The largest interaction interface (901 A˚2) displays excellent
shape complementarity as observed from the surface represen-
tation of interfacing molecules (Figure 3A). Extensive surface
contacts are observed, primarily between identical residues at
the a1-loop-b1 from both molecules in the asymmetric unit.
Twelve residues in each molecule contribute at least 30 A˚2 to
the interface; however, residuesW211, R213, andQ318 together
contribute over 450 A˚2 of the interfacial area (Table S1 and Fig-
ure 3B). None of these three residues are conserved across
the other APOBEC3s (Figure 7). Three direct hydrogen bonds,
nine water-mediated hydrogen bonds, and one ionic interaction
occur across the entire interface (Table S2). All of these contacts
verify the intimacy of this extensive interface. As the residues
forming this extensive interface are not conserved among the
other APOBEC3s or the NTD of A3G (Figure 7), this interface
may be unique to A3G-CTD.
To assess the functional significance of this interface, a variant
of A3G was made with the three amino acid substitutions
(W211A, R213A, and R374E) designed to disrupt the observed
packing. This variant shows near undetectable levels (back-
ground) of DNA deaminase activity in vitro and abrogated anti-Structure 18,viral activity in the Vif-deficient HIV-1 reporter virus assay
(Figures 8A and 8B). Similarly, the active site A3G-E259Q variant
is catalytically dead and unable to inhibit Vif-deficient HIV-1, in
agreement with prior studies (Schumacher et al., 2008; Hache´
et al., 2008) (Figure 8B). All of the variants studied have near
normal cellular expression levels and incorporate into viral parti-
cles (Figure 8C). Thus the residues that are integral to the first
interface in the A3G191-384-2K3A crystal structure are essential
to both A3G deaminase and antiviral activity.
The second largest interface (604 A˚2) involves the b20-loop-a2
residues 247–254 in each of the two molecules of the asym-
metric unit (Figures 4A and 4B). At this interface, eight residues
of each molecule bury extensive surface area, with the largest
surface area being buried by residues F252 and F268
(Table S1). This loop also coordinates an intermolecular zinc-
binding site. H248 and H250 of one molecule in the asymmetric
unit and the secondmolecule’s C261 andD264 (through awater-
mediated hydrogen bond) coordinate an intermolecular zinc ion
(Table S2). The combination of these four residues occurring
simultaneously is unique to A3G-CTD among the APOBEC3s
(Figure 7). An additional four hydrogen/water-mediated bonds
are formed within this interface. This zinc-coordinating interface
may provide insights into how a metal-mediated switch could
specifically modulate A3G oligomerization.28–38, January 13, 2010 ª2010 Elsevier Ltd All rights reserved 31
Figure 4. Interface 2 between Two A3G-
CTD Molecules in the Asymmetric Unit
Surface representation (A) and detailed interac-
tions (B). Same coloring scheme as in Figure 3.
(C) Interface 2 overview with coloring based on
data from HSQC spectra. Blue residues: signal
lost (I192, L193, S196, M197, D198, N208, R215,
Y219, L220, Y222, V224, R238, R239, G240,
A243, N244, Q245, A246, L253, E254, G255,
R256, H257, L260, C261, F262, L263, V265,
F268, W269, W285, S286, I314, G319, L325,
F350, D352, S368, L371, and R374); yellow resi-
dues: chemical shift indicating fast exchange
(T201, T203, F204, W211, T218, E225, K234,
D264, K270, L271, D316, T327, A333, I337,
T339, S341, S372, G373, and R376).
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at this interface. Through titration of Zn2+ into isotope-labeled
A3G191-384-2K3A, loss of signal intensities and chemical shift
perturbations were observed at 1 mM Zn2+ (Figure S2, labeled
blue). The residues most affected are located in the b20-loop-a2
and a2 regions. In fact, these residues in the A3G191-384-2K3A
crystal structure (Figure 4C, blue) map predominantly to the
zinc-coordinating second interface, described above, indicating32 Structure 18, 28–38, January 13, 2010 ª2010 Elsevier Ltd All rights reservedthat this interface may contribute to zinc-
mediated oligomerization in solution.
To test the ability of zinc to modulate
oligomerization, a further series of NMR
experiments was performed. A reference
heteronuclear single quantum coherence
(HSQC) spectrum was taken at 50 mM
of Zn2+ concentration (Figure 9A), and
then, Zn2+ concentration was increased
to 1.25 mM, causing the disappearance
of amide proton NMR signals (Figure 9B).
Next, 0.4 mM ethylenediaminetetraacetic
acid (EDTA) was added to chelate the free
Zn2+. This caused the signals within the
NMR spectra to reappear (Figure 9C).
The similarity of chemical shifts, signal
intensities, and line shapes of HSQC
signals in Figures 9A and 9C combine to
suggest that zinc may mediate the equi-
librium of A3G-CTD between oligomeric
(Figure 9B) and monomeric states.
A variant designed to disrupt this zinc
binding site in the second interface
(H248A, H250A, and C261A) shows
normal expression levels and antiviral
activity (Figures 8B and 8C). These obser-
vations demonstrate that zinc-mediated
oligomerization may not be essential for
A3G’s HIV-1 restriction activity. This
variant is partly defective for DNA deam-
inase activity (Figure 8A). This alteration
in DNA deaminase activity may be attrib-
utable to C261A alone (Chen et al., 2008)
and was not significant enough to com-promise A3G antiviral activity. Thus the residues that are integral
to the second interface in the A3G191-384-2K3A crystal struc-
ture appear to slightly impact A3G deaminase activity.
The third interface (427 A˚2) involves residues at N-terminal
(b1-b2 strands) and C-terminal ends of A3G191-384-2K3A
(Figures 5A and 5B and Table S1). Nine residues contribute
extensively to the interface with Q354 burying the largest surface
area at this interface followed by Q237, H228, and G355. In six of
Figure 5. Interface 3 between Two A3G-CTDMolecules in the Asym-
metric Unit
Surface representation (A) and detailed interactions (B). Same coloring
scheme as in Figure 3.
Figure 6. Interface 4 between Two A3G-CTDMolecules in the Asym-
metric Unit
Surface representation (A) and detailed interactions (B). Same coloring
scheme as in Figure 3.
Structure
Correct APOBEC3G Catalytic Domain Crystal Structurethe eleven aligned APOBEC3 sequences (Q or E354)/G355 are
conserved (Figure 7) but not H228 or Q237. Four direct and three
water-mediated hydrogen bonds are formed at this interface.
Specifically, Q237 and R238 at the b2-b20 bulge of one molecule
(molecule A) form intermolecular hydrogen bonds to N-terminal
residues R194 (side chain disordered) and S196 with the other
molecule (molecule B). In addition, Q354 in the a5-a6 loop (mole-
cule B) forms a hydrogen bondwith R226 in b1 (molecule A). This
interaction is potentially conserved in APOBEC3A and APO-
BEC3B-CTD. This interface would correspond closest to the
b2-b2 interface observed in APOBEC2, but is clearly not formed
and would entail extensive rearrangement of the a5 and a6
helices and their connecting loop. Of the four major interfaces,
the packing of the third interface is least complementary and
mutations at this interface (H228A, V233R, and L235R) do not
disrupt A3G’s DNA deaminase or antiviral activities (Figure 8).
The final of the four major interfaces buries a total of 246 A˚2
and involves substantial burial of six residues from each mole-
cule and the formation of two hydrogen bonds and a salt bridge
(Figures 6A and 6B and Tables S1 and S2). This interface is
primarily made up of the tops of the a5 and a6 helices. Interest-
ingly, residues in a5 and a6 are also affected by the addition of
Zn2+. These residues showed small chemical shift changes inStructure 18,HSQC spectra, suggesting that this region is involved in intermo-
lecular interactions under a fast exchange (Figure 4C and
Figure S2, yellow). At this interface, residues Y340 and D365
contribute most to the buried interface area. These two residues
are well conserved among the various APOBEC3s (Figure 7),
Y340 is conserved in all but one, and (D/E/Q)365 is conserved in
eight of the eleven APOBEC3 sequences. Both of these residues
and the less conserved S341 are involved in hydrogen bonding;
a salt bridge is observed between the moderately conserved
K344 and D365. Although extensive sequence conservation is
present, this interface is not as large as the others and a variant
of A3G with mutations Y340A, S341A, K344A, and D365A has
normal DNA deaminase and HIV-1 restriction activities (Figure 8).
DISCUSSION
In this study, the crystal structure of the catalytically active
C-terminal domain of APOBEC3G was determined to 2.25 A˚.
This structure differs significantly from the previously published
crystal structure of this domain (PDB 3E1U) (Holden et al., 2008).28–38, January 13, 2010 ª2010 Elsevier Ltd All rights reserved 33
Figure 7. Multiple Sequence Alignment of
all Human APOBEC3 Protein Sequences
(Refseq) by Their Respective NTDs and
CTDs Aligned to the A3G-CTD Sequence
Residues contributing more than 30 A˚2 to the
buried surface area on an intermolecular interface
are highlighted. Secondary structure elements of
the A3G191-384-2K3A structure are shown sche-
matically above the sequence as brown rectan-
gles for a helices, yellow arrows for b strands,
and black lines for loop regions.
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deposited experimental data do not unambiguously describe
the structure deposited in the PDB. In contrast, our well-resolved
crystal structure of A3G191-384-2K3A validates the published
mutant and wild-type NMR structures (Chen et al., 2008;
Furukawa et al., 2009; Harjes et al., 2009), both in respect to
the b2-b20 bulge and a longer a2 helix with the residues F268-
D272 placed properly. Thus, this structure represents the first
clearly resolved crystal structure of the catalytic domain of
APOBEC3G.
In addition, mass spectrometry data support the observed
b1-b2 conformation and presence of a bulge between the b2-
b20 strands of the A3G catalytic domain. We verified the register
of the b1-b2 secondary structure elements by probing the prox-
imity of key residues in this region through carefully engineered
disulfide linkages. These results confirm the structural integrity
of the b1-b2 conformation observed in all NMR structures and
the A3G191-384-2K3A crystal structure described here (Chen
et al., 2008; Furukawa et al., 2009; Harjes et al., 2009).
The unique interfaces observed between the asymmetric units
of this crystal structure also lend insights into the potential role of
oligomerization in APOBEC3G function. Full-length APOBEC3G
sequence displays pseudosymmetry (Figure 7), yet none of the
largest interfaces observed in the crystal structure are conserved
between the N- and C-terminal halves of the protein sequence
nor do they position the termini in a manner that could represent
the full-length enzyme. This is also consistent with the recent
model proposed for the full-length A3G holoenzyme (Harjes
et al., 2009).
Beyond the full-length A3G enzyme, oligomerization—often
dimerization or tetramerization—is a trend among the known
deaminases. Escherichia coli cytidine deaminase and Staphylo-34 Structure 18, 28–38, January 13, 2010 ª2010 Elsevier Ltd All rights reservedcoccus aureus TadA form dimers;
Bacillus subtilis cytidine deaminase,
yeast CDD1, and human cytidine deami-
nase form tetramers; and human ADAR1
and ADAR2 are homodimers (Betts
et al., 1994; Carlow et al., 1999; Chung
et al., 2005; Johansson et al., 2002; Losey
et al., 2006; Navaratnam and Sarwar,
2006; Valente and Nishikura, 2007; Xie
et al., 2004). Multiple studies have shown
that A3G can exist in states ranging from
monomer to megadalton complexes
(Bennett et al., 2008; Chiu et al., 2006;
Jarmuz et al., 2002; Wedekind et al.,2006). The importance of A3G oligomerization to HIV-1 suppres-
sion is controversial; some studies conclude that oligomerization
is dispensable (Opi et al., 2006) while others claim that oligomer-
ization is essential (Huthoff et al., 2009). The present study adds
new insights into the potential roles of these interfaces for anti-
viral and deaminase activities.
The surface of A3G that forms these oligomers still remains
unclear. SAXS, coimmunoprecipitation, and FRET studies have
implicated the C-terminal half of A3G in oligomerization (Bennett
et al., 2008; Wedekind et al., 2006). This work potentially con-
trasts with more recent coimmunoprecipitation studies demon-
strating that N-terminal residues are required for RNA-mediated
dimerization (Huthoff et al., 2009; Friew et al., 2009). Possibly
both sets of studies have some merit and two or more distinct
surfaces of A3G contribute to oligomerization.
Based on our analyses and data, we hypothesize that there are
a variety of potential surfaces for oligomerization. The interac-
tions observed at the two most extensive interfaces, the
a1-loop-b1 (Figure 3) and the b20-loop-a2 (Figure 4), which coor-
dinates a zinc ion, represent unique A3G homooligomerization
interfaces, while the tops of the a5 and a6 helices (Figure 6) could
modulate both homo- and heterooligomerization of the different
APOBEC3 family members.
A combination of solution NMR and the impact of variants de-
signed to disrupt the interfaces supports the possibility that three
of these interfaces may have functional significance. Mutations
introduced to disrupt the first interface reduce both DNA deam-
inase activity and antiviral activity of A3G (Figure 8). However,
whether this change in activity is due to a change in oligomeriza-
tion or direct disruption in nucleic acid binding affinity remains to
be determined. While mutations to disrupt the other interfaces
do not alter the antiviral activity of A3G, these interfaces still
AB
C
Figure 8. DNA Deaminase Activity and HIV-1 Restriction Data
(A) A graph showing the results of a DNA oligonucleotide-based deamination
assay with the indicated A3G-GFP constructs [MOCK, GFP only; WT, A3G-
GFP; E259Q, A3G-E259Q-GFP; INT1, interface 1 A3G-GFP mutant (W211A,
R213A, R374E); INT2, interface 2 A3G-GFP mutant (H248A, H250A, C261A);
INT3, interface 3 A3G-GFP mutant (H228A, V233R, L235R); INT4, interface 4
A3G-GFP mutant (Y340A, S341A, K344A, D365A)]. The y axis reports the rela-
tive fluorescence level (C-to-U activity) and the x axis shows the amount of
A3G-expressing cell lysate used in each reaction. In most instances the SD
of three replicas was smaller than the symbol.
(B) A histogram showing the relative infectivity of Vif-deficient HIV-GFP
produced in the presence of the indicated A3G-GFP expression constructs
or a GFP vector control. This histogram presents the average of two indepen-
dent experiments, each with three replicas. The error bars show the relative
difference between the two data sets.
(C) Immunoblots of cellular lysates and virus particles probed for A3G-GFP,
CA, and tubulin using anti-GFP, anti-p24, and anti-tubulin antibodies, respec-
tively.
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Correct APOBEC3G Catalytic Domain Crystal Structuremay impact oligomerization. The solution NMR data demon-
strate a clear relationship between zinc-mediated EDTA-revers-
ible oligomerization and specific chemical shifts of residuesmost
strongly in the second interface that binds the intermolecularStructure 18,zinc but secondarily to the fourth interface (Figure 9 and Fig-
ure S2). The functional significance of the zinc-mediated oligo-
merization remains to be elucidated. The interfaces observed
in this newA3G-CTD crystal structuremay therefore have impor-
tant functional implications in the role of oligomerization for the
activity of A3G and will guide future studies.
EXPERIMENTAL PROCEDURES
Protein Expression and Purification
BL21(DE3)-CodonPlus(RIL) (Stratagene) bacterial cells, transformed with the
pGEX6P1-A3G191-384-2K3A vector (Chen et al., 2007; Harjes et al., 2009),
were grown to an OD600 of 0.6 (TB media, 100 mg/ml ampicillin, and 34 mg/ml
chloramphenicol). They were induced overnight (0.5 mM IPTG, 18C) to
express GST-A3G191-384-2K3A. The cells were then harvested by centrifu-
gation (5000 rpm, 15 min, 4C) and resuspended in lysis buffer [50 mM
Na2HPO4/NaH2PO4 (pH 7.4) and protease inhibitor (Roche)]. Resuspension
was followed by lysis with a cell disruptor. The lysate was centrifuged
[43,000 3 g, 20 min, 4C] and the supernatant was incubated overnight with
glutathione-Sepharose (GE Healthcare) beads. The beads were washed with
lysis buffer and incubated with PreScission Protease (GE Healthcare) in
cleavage buffer [50 mM Na2HPO4/NaH2PO4 (pH 7.4), 0.005% Tween20, and
1mMdithiothreitol]. A3G191-384-2K3A in the supernatant was further purified
by FPLC (GE Healthcare) using a Superdex-75 size-exclusion column.
Protein Crystallization
Purified A3G191-384-2K3A protein was exchanged into crystallization buffer
[50 mM HEPES (pH 7.5), 1 mM tris(2-carboxyethyl)phosphine, 50 mM zinc
acetate, and 150 mM NaCl] with a PD-10 column (GE Healthcare). The protein
was concentrated to 10 mg/ml using Amicon centrifugal filters (Millipore).
Crystals were grown by the hanging-drop/vapor-diffusion method on greased
VDX plates (Hampton Research) at 4C with the reservoir solution [100 mM
HEPES (pH 7.5), 10% Polyethylene glycol 4000, and 100 mM magnesium
chloride].
Data Collection and Processing
Diffraction data for the A3G191-384-2K3A protein crystals were collected by
synchrotron radiation at Argonne National Laboratory (Advanced Photon
Source, Chicago, IL) BioCARS 14-BMC under cryogenic conditions. Dif-
fraction images were indexed and scaled using the program HKL2000 (Otwi-
nowski and Minor, 1997); the structure was solved in P212121 space group
at 2.25 A˚.
Structure Solution and Refinement
The molecular replacement solution, calculated by PHASER (McCoy et al.,
2007) with the final translation function Z score of 41.1, contained two mole-
cules in the asymmetric unit. Phases were subsequently improved by building
solvent molecules using ARP/wARP (Langer et al., 2008). Refinement was
carried out with REFMAC5 (Murshudov et al., 1997) in the CCP4 suite
(CCP4, 1994), with cycles of rigid body and restrained refinement; Non-crys-
tallographic symmetry restraints were applied in the first two cycles and TLS
parameters (Painter and Merritt, 2006) were used in subsequent refinement
cycles. A free R value with 5% of the data was used to limit the possibility of
over-refinement. Electron density was viewed by the program COOT (Emsley
and Cowtan, 2004) and was used for model optimization.
Structure Comparison and Analysis
Graphical visualization and analysis was achieved using PyMOL (DeLano
Scientific LLC) (DeLano, 2002). The interaction interfaces formed between
molecules in the A3G191-384-2K3A crystal were analyzed by the Protein
Interfaces, Surfaces, and Assemblies Service (PISA) at the European Bioinfor-
matics Institute (Krissinel and Henrick, 2007). The NOE violations were calcu-
lated using the accept.inp protocol of CNS (Bru¨nger et al., 1998). The A3G-
CTD crystal structure (PDB 3E1U) was used as the input coordinate file and
the NOE files used to calculate the A3G191-384-2K3A NMR structure (PDB
2KEM) were set as NOE distance restraints. The algorithm PRANK, as imple-
mented in the software PRANKSTER, performed the multiple sequence28–38, January 13, 2010 ª2010 Elsevier Ltd All rights reserved 35
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Figure 9. Zn2+-Dependent A3G191-384-2K3A Aggregation is Reversible
HSQC spectra of A3G191-384-2K3A with 50 mMZn2+ (A), 1.25mM Zn2+ (B), and 1.25mM Zn2+, 0.4mM EDTA (C). Protein concentration was 300 mM for all
spectra.
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Correct APOBEC3G Catalytic Domain Crystal Structurealignments, with the +F option and default values (Loytynoja and Goldman,
2005). All human APOBEC3 sequences were downloaded from the NCBI
Refseq database (APOBEC3A: NP_663745.1; APOBEC3B: NP_004891.3;
APOBEC3C: NP_055323.2; APOBEC3DE: NP_689639.2; APOBEC3F:
NP_660341.2; APOBEC3G: NP_068594.1; APOBEC3H: NP_861438.1) (Pruitt
et al., 2007).DNA Deaminase Activity Assays
The A3G-GFP and A3G-E259Q-GFP expression constructs have been
described previously (Stenglein et al., 2008; Schumacher et al., 2008). All
derivatives were constructed by combinatorial or sequential site-directed
mutagenesis (Stratagene), with primer sequences available on request. The
indicated A3G-GFP or interface mutant expression constructs were trans-
fected into HEK293T cells using TransIT-LTI (Mirus Bio). Cell lysates were
prepared and DNA deaminase activities were measured as described (Thielen
et al., 2007). The sequence of the single-strand DNA substrate was 50-(6-FAM)-
AAA-CCC-AAA-GAG-AGA-ATG-TGA-(TAMRA).HIV-1 Infectivity Studies and Immunoblots
HIV-1 infectivity studies and immunoblots were performed as described
(Harjes et al., 2009). HIV-GFP reporter viruses were produced by TransIT-
LTI-mediated transfection (Roche) of HEK293T cells with a five plasmid cock-
tail (Liddament et al., 2004). The HIV-GFP proviral plasmid CS-CG, the Gag-
Pol expression plasmid, the Rev expression plasmid, and the VSV-G envelope
expression plasmid constituted 0.97 mg of the cocktail and the vector control
or the A3G expression plasmid constituted the remaining 0.03 mg. Viruses
were harvested 48 hr after transfection by filtering cell-free supernatants
(0.22-mm PVDF; Millipore) and pelleting by centrifugation (20,000 3 g for
2 hr). The resulting viral pellet was resuspended directly in SDS gel loading
buffer, fractionated by SDS-PAGE, transferred to PVDF membrane (Millipore),
and probedwith an anti-GFP antibody JL-8 (Invitrogen) to detect the A3G-GFP
constructs. An anti-p24 monoclonal antibody (Simon et al., 1997) provided by
M. Malim through the National Institutes of Health AIDS Research and Refer-
ence Reagent Program was used as loading control. Both monoclonal anti-
bodies were detected using a horseradish peroxidase-conjugated goat anti-
mouse IgG serum (Bio-Rad), followed by chemiluminescent imaging (Roche).
After harvesting the viral supernatants, A3G levels in virus-producing cells
were monitored by extracting soluble proteins with RIPA buffer (1 hr, 4C,
gentle rotation), removing particulates by centrifugation (20,000 3 g for36 Structure 18, 28–38, January 13, 2010 ª2010 Elsevier Ltd All right10 min), and immunoblotting, as described above. An anti-tubulin monoclonal
antibody (Covance) was used as cellular lysate loading control.
NMR Zn2+ Titration Experiments
15N-labeled A3G191-384-2K3A protein was expressed and purified [in 1 mM
DTT, 200 mM NaCl, 0.005% Tween 20 (Fisher scientific), and 50 mM tris(hy-
droxymethyl)aminomethane buffer (pH 8.0)] as described in Harjes et al.
(2009). ZnCl2 was titrated into 300 mM
15N-labeled A3G191-384-2K3A at
concentrations of 50 mM, 200 mM, 400 mM, 600 mM, 800 mM, 1 mM, and
1.25mM. AnHSQC spectrumwas recorded at each Zn2+ concentration, which
enabledspecific aminoacid chemical shift perturbations tobedetected.Bruker
700 MHz equipped with a cryoprobe was used to collect all NMR spectra.
Mass Spectrometry of Cysteine Mutants
Cysteine substitution variants were constructed using QuikChange protocol
(Stratagene) and verified by DNA sequencing. A3G191-384-2K3A, A3G191-
384-2K3A-M227C-W232C, A3G1-384-M227C-W232C, and A3G1-384-
R226C-L235C were produced using the same procedure as described in the
Protein Expression and Purification section. Proteins were isolated from
SDS polyacrylamide gel after Coomassie brilliant blue staining. Isolated
protein bands were digested using trypsin and subjected to mass spectrom-
etry at the Taplin Biological Mass Spectrometry Facility (Harvard Medical
School). Both high resolution full mass spectrometry scans and high resolution
mass spectrometry/mass spectrometry scans were performed using LTQ-FT
and LTQ-Orbitrap (Thermo Electron) to verify the peptide.
SUPPLEMENTAL INFORMATION
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